

# Neuronetics

## Neuronetics to Report First Quarter 2026 Financial and Operating Results and Host Conference Call

April 21, 2026

MALVERN, Pa., April 21, 2026 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM) (the "Company"), a medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders and the maker of NeuroStar® Advanced Therapy, today announced that it plans to release first quarter 2026 financial and operating results prior to market open on Tuesday, May 5, 2026. The Company will host a conference call to review its results at 8:30 a.m. Eastern Time the same day.

The conference call will be broadcast live in listen-only mode via webcast at <https://edge.media-server.com/mmc/p/3pztkve5>. To listen to the conference call on your telephone, participants may register for the call [here](#). While it is not required, it is recommended you join 10 minutes prior to the event start.

### About Neuronetics

Neuronetics, Inc. believes that mental health is as important as physical health. As a global leader in neuroscience, Neuronetics is delivering more treatment options to patients and physicians by offering exceptional in-office treatments that produce extraordinary results. NeuroStar Advanced Therapy is a non-drug, noninvasive treatment that can improve the quality of life for people suffering from neurohealth conditions when traditional medication has not helped. In addition to selling the NeuroStar Advanced Therapy System and associated treatment sessions to customers, Neuronetics operates Greenbrook TMS Inc. ("Greenbrook") treatment centers across the United States, offering NeuroStar Advanced Therapy for the treatment of major depressive disorder ("MDD") and other mental health disorders. NeuroStar Advanced Therapy is the leading transcranial magnetic stimulation ("TMS") treatment for MDD in adults, and is backed by the largest clinical data set of any TMS treatment system for depression, including the world's largest depression outcomes registry. Greenbrook treatment centers also offer SPRAVATO® (esketamine) nasal spray, a prescription medicine indicated for the treatment of treatment-resistant depression in adults as monotherapy or in conjunction with an oral antidepressant. It is also indicated for depressive symptoms in adults with major depressive disorder with acute suicidal ideation or behavior in conjunction with an oral antidepressant.<sup>1</sup>

The NeuroStar Advanced Therapy System is cleared by the U.S. Food and Drug Administration for adults with MDD, as an adjunct for adults with obsessive-compulsive disorder, to decrease anxiety symptoms in adult patients with MDD that may exhibit comorbid anxiety symptoms (anxious depression), and as a first line adjunct for the treatment of MDD in adolescent patients aged 15-21. For safety information and indications for use, visit [NeuroStar.com](http://NeuroStar.com).

### Investor Contact:

Mike Vallie or Mark Klausner  
ICR Healthcare  
443-213-0499  
[ir@neuronetics.com](mailto:ir@neuronetics.com)

### Media Contact:

EvolveMKD  
646-517-4220  
[NeuroStar@evolvemkd.com](mailto:NeuroStar@evolvemkd.com)

### References

<sup>1</sup> The effectiveness of SPRAVATO® in preventing suicide or in reducing suicidal ideation or behavior has not been demonstrated. Use of SPRAVATO® does not preclude the need for hospitalization if clinically warranted, even if patients experience improvement after an initial dose of SPRAVATO®. For more important safety information about SPRAVATO®, please visit [spravatohcp.com](http://spravatohcp.com).

# Neuronetics

Source: Neuronetics